Caribou Biosciences faces a critical liquidity inflection point as its chRDNA platform development continues to outpace its ability to generate sustainable, non-milestone-dependent revenue. While the company maintains a low debt-to-equity ratio of 0.26, the ra...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.24+25.9% vs -$0.32 | $1M-34.2% vs $2M |
Q3 2026 Aug 12, 2026 | -$0.24+25.9% vs -$0.32 | $2M-34.2% vs $2M |
Q2 2026 May 7, 2026 | -$0.26+21.2% vs -$0.33 | $2M+8.3% vs $2M |
Q2 2026 Mar 5, 2026 | -$0.28+15.2% vs -$0.33 | $4M+78.6% vs $2M |
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BlackRock Inc. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ: CRBU) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,815,843 shares of the company's stock, valued at approximately $13,756,000. BlackRock Inc. owned about 7.88% of Caribou Biosciences
Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.
Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating
Benchmark CRBU against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Caribou Biosciences, Inc. (CRBU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.22 | $121M | -0.77 | 11.66% | -1327.4% | -78.97% | — | |
| $2.62 | $402.07M | -1.46 | 25.39% | -157.32% | -196.63% | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — | |
| $55.43 | $5.35B | -8.57 | -89.97% | -3368.72% | -24.39% | — | |
| $2.32 | $270.42M | -2.02 | -51.24% | -1941.09% | -65.08% | — |
Caribou Biosciences, Inc. (CRBU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Caribou Biosciences, Inc. (CRBU) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 18, 2026·SEC
Jun 11, 2026·SEC
Get notified when CRBU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Caribou Biosciences, Inc. (CRBU) stock FAQ — growth, dividends, profitability & financials explained
Caribou Biosciences, Inc. (CRBU) reported $10.0M in revenue for fiscal year 2025. This represents a 73% increase from $5.8M in 2019.
Caribou Biosciences, Inc. (CRBU) grew revenue by 11.7% over the past year. This is steady growth.
Caribou Biosciences, Inc. (CRBU) reported a net loss of $103.4M for fiscal year 2025.
Caribou Biosciences, Inc. (CRBU) has a return on equity (ROE) of -79.0%. Negative ROE indicates the company is unprofitable.
Caribou Biosciences, Inc. (CRBU) had negative free cash flow of $95.8M in fiscal year 2025, likely due to heavy capital investments.
